Back to Search
DANIEL JOSEPH ALLENDORF M.D.
M.D.
Student in an Organized Health Care Education/Training Program
NPI: 1073716163IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Education
UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE
Class of 2003
Research & Publications (12)
The role of membrane complement regulatory proteins in cancer immunotherapy.
PMID 19025121·Adv Exp Med Biol·2008
6-review
Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.
PMID 17671212·Cancer Res·2007
7-preclinical
Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice.
PMID 17597024·Folia Histochem Cytobiol·2007
7-preclinical
Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury.
PMID 16179370·Blood·2006
4-observational
Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.
PMID 16849475·J Immunol·2006
7-preclinical
Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.
PMID 15934844·Expert Opin Biol Ther·2005
6-review
C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan.
PMID 15905548·J Immunol·2005
4-observational
Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow.
PMID 14604969·Blood·2004
7-preclinical
Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells.
PMID 15284858·Leukemia·2004
7-preclinical
Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
PMID 15240666·J Immunol·2004
7-preclinical
Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
PMID 14695221·Cancer Res·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 619 19TH ST S
BIRMINGHAM, AL 35249 - Phone
- (205) 934-5038
Quick Facts
- NPI
- 1073716163
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 23
- Publications
- 12
Are you this provider?
Claim Your Profile